Cefalu 2015

NCT01031680

1 Treatments

Studied treatment  Dapagliflozin 10 mg tablet, oral, once daily, 24-week

Control treatment  placebo

Concomittant treatments  Pts With T2DM, CV Disease and Hypertension Who Exhibit Inadequate Glycaemic Control on Usual Care

2 Patients

Patients -

Inclusion criteria -

Exclusion criteria -

3 Methods

Blinding -

Design -

Centers -

Geographical area -

Sizes -9/-9

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>MI</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
</tr>
<tr>
<td>all cause deaths</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
</tr>
<tr>
<td>CV events</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
</tr>
<tr>
<td>CV deaths</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
</tr>
<tr>
<td>stroke</td>
<td>-/9</td>
<td>-/9</td>
<td>NA</td>
</tr>
</tbody>
</table>
5 References
